Icagen has reported top-line results from its phase IIa exercise-induced asthma study, senicapoc. The trial failed to demonstrate improvement in the primary study endpoints, including maximum decrease in
GlaxoSmithKline (GSK) and Genmab have received accelerated approval for Arzerra (ofatumumab) from the FDA for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine
BioMarin Pharmaceutical has acquired Huxley Pharmaceuticals, which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).
The FDA has reviewed and has allowed the use of twelve new structural health claims filed for Algatechnologies’ AstaPure brand of natural astaxanthin in the US market. Reportedly,
The University of Southampton has received a $100,000 grant from the Bill & Melinda Gates Foundation. The researchers team, led by microbiologist Jeremy Webb, was awarded funding to
Scynexis has received a payment from Merck, for achieving a preclinical milestone resulting from a collaboration to discover and develop novel oncology agents. Yves Ribeill, president and CEO
We are looking to find out how readers are expecting the market to perform into 2010, what will be the key sectors, trends and spending areas, and where
Sinovac Biotech has received third purchase order for its H1N1 vaccine, PANFLU.1, from China’s Ministry of Industry and Information Technology for the national stockpiling plan. Under the purchase
Astellas Pharma (Astellas) and Medivation have entered into a global agreement to develop and commercialise MDV3100, Medivation’s investigational drug for the treatment of prostate cancer. MDV3100 is currently
Alkermes has initiated phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.